Honest Company stock vaulted 15.9% in pre-open trading following the release of the company's second-quarter 2026 financial results, which were posted after the market close the previous session. The pre-market move pushed shares past the prior 52-week high of $4.378 to $4.461.
The quarterly report showed net income of $10.7 million and a substantial improvement in profitability, with gross margin rising by 800 basis points to 48.4%. In her comments on the results, CEO Carla Vernon said, "For the second quarter we delivered accelerated Organic Revenue growth of 7% and record underlying margins," and noted that consumption growth of nearly 8% points to durable momentum across the company’s fastest-growing, most profitable platforms.
On the top line, the company reported revenue of $83.3 million, down 10.9% year-over-year. Management attributed that decline to strategic product exits and a pullback in diaper sales. By contrast, organic revenue increased 6.7% to $80.2 million, driven primarily by gains in wipes and personal care categories.
Management updated its outlook for the full year 2026, raising the revenue range to $319 million to $325 million and nudging projected Adjusted EBITDA to $23 million to $25 million. The results and revised guidance prompted a strong market reaction, with investors responding to the combination of an earnings beat, margin expansion and a firmer outlook.
Balance sheet metrics were highlighted as a source of investor comfort. Honest Company reported $105.9 million in cash and no debt as of June 30. The company repurchased 5.6 million shares for $18.7 million during the first half of the year, a use of capital that, together with the cash position and lack of debt, helped reassure the market.
On the analyst front, Telsey Advisory lifted its price target on Honest Company to $5 from $4 while retaining a Market Perform rating.
The pre-market rally appeared to be driven by company-specific developments rather than broader market strength. The S&P 500 was essentially flat at +0.1% while the Nasdaq slipped 0.7%, and there were no major central bank announcements or notable economic data releases reported that would have materially altered sentiment in the personal care sector during the morning session.
Taken together, investors cited multiple factors supporting the stock's re-rating: a sizable earnings-per-share beat, record margins, accelerating organic sales growth, a strong cash position with no debt, and an upgraded full-year outlook. With an all-time low of $1.06 and the new pre-market price of $4.461 establishing a 52-week high, the move represents a notable turning point in the company’s recovery narrative.